Volume 5, Issue 3 (Summer 2024)                   J Vessel Circ 2024, 5(3): 0-0 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jamali M, Zarei Taher T, Rouientan H, Ahmadzade M, Noorbakhsh N, Kavianpour M. Consolidative Allogeneic Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy for Acute Lymphoblastic Leukemia. J Vessel Circ 2024; 5 (3)
URL: http://jvessels.muq.ac.ir/article-1-286-en.html
Consolidative Allogeneic Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy for Acute Lymphoblastic Leukemia
Marzieh Jamali * 1, Tahereh Zarei Taher , Hamidreza Rouientan , Mohadese Ahmadzade , Negar Noorbakhsh , Maria Kavianpour
Abstract:   (19 Views)
Patients with refractory or relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL) have a poor prognosis and few therapy choices. Chimeric antigen receptors (CAR)-T cell therapy is a turning point in contemporary cell and gene treatments, answering an unmet need for high-risk patient treatment and bringing immunotherapies closer to cancer drugs, particularly hematologic malignancies. Many clinical trials have demonstrated that CAR-T cell treatment can reach 70 to 90% complete remission (CR) rates. Despite the potential benefits, it is worth noting that remission induced by CAR-T cell therapy may not last indefinitely. In fact, research indicates that between 30 to 60% of patients experience a relapse at some point following treatment. Due to successful remission achieved through CAR-T cell therapy, there have been doubts among researchers regarding the need for consolidative allogeneic hematopoietic stem cell transplantation (ALLO-HSCT). The use of CAR-T cell therapy as a temporary treatment or definitive solution before ALLO-HSCT is still a topic of debate due to insufficient reliable evidence. We look at the clinical evidence for consolidative ALLO-HSCT after CAR-T cell therapy, as well as the factors that may influence the benefit of ALLO-HSCT. Finally, we offer advice on assessing and managing R/R B-ALL patients receiving CAR-T cell therapy.
 
Keywords: CAR-T cells, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia, Relapse.
     
Type of Study: Review | Subject: hematology
Received: 2024/08/16 | Accepted: 2025/03/26 | Published: 2024/12/31
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Vessels and Circulation

Designed & Developed by : Yektaweb